Postoperative Pain Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Postoperative Pain Therapeutics | DelveInsight

DelveInsight's Postoperative Pain Pipeline Insight 2026 report provides comprehensive global coverage of available and pipeline Postoperative Pain therapies across various stages of clinical and nonclinical development. More than 40 companies are working to advance 50+ pipeline drugs, with pharmaceutical and biotechnology companies developing novel therapeutic approaches focused on improving postoperative pain management and addressing the limitations associated with conventional analgesic therapies.

Key takeaways from the Postoperative Pain Clinical Trial Landscape Report

• DelveInsight's Postoperative Pain pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Postoperative Pain treatment.
• Key Postoperative Pain companies such as Ensysce Biosciences, Nevakar, Sustained Therapeutics, Concentric Analgesics, G2GBIO, LipoCure, Bexson Biomedical, Allay Therapeutics, and others are involved in developing therapies for the indication.
• Promising Postoperative Pain pipeline therapies in various stages of development include PF614, NVK-009, ST-01, CA-008, GB-6002, LC-400, BB-106, ATX-201, and others.
• The Postoperative Pain pipeline includes Phase III, Phase II, Phase I, preclinical, discovery, discontinued, and inactive candidates, reflecting a diverse therapeutic development landscape.
• Ensysce Biosciences has PF614 in the most advanced development stage highlighted in the report, Phase III.

Request a sample and discover the recent advances in Postoperative Pain treatment drugs:
https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Postoperative Pain?
Postoperative pain is a complex physiological and psychological response to surgery, generally resulting from tissue damage, inflammation, and the body's stress response. Effective management of postoperative pain is important for recovery because uncontrolled pain can interfere with healing, increase the risk of complications, delay recovery, and potentially contribute to chronic pain.
Acute postoperative pain generally occurs immediately following surgery and may last for days to weeks because of tissue injury and inflammation. Chronic post-surgical pain persists for more than three months and may affect 10-50% of patients, depending on the type of surgery and individual risk factors. Neuropathic pain may also occur when surgery causes nerve damage, resulting in burning, tingling, or shooting sensations.
Surgical injury to tissues and nerves can activate inflammatory pathways and alter pain processing. Peripheral nerve injury may increase sodium-channel expression in sensitized nerves, leading to spontaneous activity and increased glutamate release. Glutamate can act on receptors such as NMDA and AMPA, contributing to central sensitization and amplification of pain signals within the spinal cord.
The intensity of postoperative pain varies according to the type of surgery, with procedures involving substantial tissue trauma, including orthopedic, thoracic, and abdominal surgeries, generally associated with more severe pain. Age, sex, genetics, previous pain experiences, anxiety, depression, and expectations regarding postoperative pain can also influence pain perception.
Management commonly involves a step-wise and balanced approach. Multimodal analgesia combines two or more analgesic agents with different mechanisms of action to achieve pain relief while limiting adverse effects. Common intravenous opioid analgesics include morphine, hydromorphone, and fentanyl.

Emerging Postoperative Pain Drug Profiles

PF614: Ensysce Biosciences
PF614 is an oxycodone-based pain medication that has been chemically modified to remain inactive until swallowed, where digestive enzymes activate and release oxycodone. The therapy is designed to provide pain relief for severe pain requiring opioid treatment.
PF614 uses Ensysce's TAAPTM technology, which chemically modifies the opioid to provide controlled activation after oral administration. According to the DelveInsight report, PF614 is designed to provide approximately 12 hours of pain relief per dose and can be taken with or without food. PF614 is currently in Phase III development for Postoperative Pain.

ATX101: Allay Therapeutics
ATX101 is an investigational formulation combining bupivacaine, an established intracellular sodium ion channel blocker, with a biopolymer designed to provide prolonged postoperative analgesia. The formulation is intended to provide weeks of pain relief following total knee arthroplasty.
ATX101 is placed at the end of standard surgery and is designed to provide ultra-sustained local analgesia before eventually dissolving into water and carbon dioxide. The approach is intended to reduce reliance on complex combinations of shorter-acting analgesic products used following surgery. ATX101 is currently in Phase II clinical development for Postoperative Pain.

LC-400: LipoCure
LC-400 is an ultra-long-acting local anesthetic (ULALA) developed by LipoCure to provide extended postoperative pain relief following a single administration. It consists of a multi-vesicular liposome hydrogel formulation containing bupivacaine, enabling controlled and prolonged drug release.
By maintaining sustained bupivacaine levels at the target site, LC-400 is designed to reduce the need for additional analgesics such as NSAIDs or opioids and potentially reduce their associated side effects. Phase I clinical studies have generated initial data supporting continued development, with the drug advancing toward Phase II trials.

GB-6002: G2GBIO
GB-6002 is an extended-release injectable formulation utilizing ropivacaine, designed for direct administration at the surgical site. The localized approach is intended to reduce systemic drug exposure while providing prolonged postoperative pain relief.
The therapy is designed to provide pain relief for more than three days following a single administration. According to the DelveInsight report, G2GBIO has completed a clinical pharmacology study demonstrating favorable pharmacokinetic results, safety, and tolerability. GB-6002 is currently in Phase I clinical development for Postoperative Pain.

Learn more about the novel and emerging Postoperative Pain pipeline therapies:
https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Postoperative Pain Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery, Discontinued & Inactive
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Postoperative Pain Companies: Ensysce Biosciences, Nevakar, Sustained Therapeutics, Concentric Analgesics, G2GBIO, LipoCure, Bexson Biomedical, Allay Therapeutics, and others
• Key Postoperative Pain Pipeline Therapies: PF614, NVK-009, ST-01, CA-008, GB-6002, LC-400, BB-106, ATX-201, and others.

Dive deep into rich insights for new drugs for Postoperative Pain treatment, visit:
https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Postoperative Pain Pipeline Report Introduction
2. Postoperative Pain Pipeline Report Executive Summary
3. Postoperative Pain: Overview
4. Postoperative Pain Pipeline Therapeutics
5. Postoperative Pain Therapeutic Assessment
6. Postoperative Pain - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. Early Stage Products (Phase I)
10. Preclinical and Discovery Stage Products
11. Inactive Products
12. Postoperative Pain Key Companies
13. Postoperative Pain Key Products
14. Postoperative Pain - Unmet Needs
15. Postoperative Pain - Market Drivers and Barriers
16. Postoperative Pain - Future Perspectives and Conclusion
17. Postoperative Pain Analyst Views
18. Postoperative Pain Key Companies
19. Appendix

For further information on the Postoperative Pain pipeline therapeutics, reach out:
https://www.delveinsight.com/sample-request/postoperative-pain-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: ksharma@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

This release was published on openPR.